My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}

Want to join the conversation?

$MYL {{ '2016-05-18T11:37:52+0000' | timeago}} • Announcement

$MYL announced an update to its indicative timetable for the commencement of the acceptance period for its recommended public offer to the shareholders of Meda Aktiebolag to tender all their shares in Meda to $MYL. $MYL now expects publication of Offer documents and commencement of the acceptance period for Offer by no later than mid-June 2016.

User Carlton Davis {{ '2016-10-24T19:31:20+0000' | timeago}}

$COL agreed to buy $BEAV for $6.4 billion in cash and stock. Also Rockwell Collins reported higher 4Q16 earnings on growth in Government Systems and higher revenue in Information Management Services.

User Charles Elliston {{ '2016-10-24T19:15:21+0000' | timeago}}

Wow! What a buzz the $T-$TWX deal is making! Almost everyone from politicians to competitors have come out against this deal. Even Wall Street doesn’t seem to be too thrilled. Both stocks were down today.

User Vishnu Beri {{ '2016-10-24T17:33:28+0000' | timeago}}

Visa ($V) set to release it earning after market close today. With new CEO resigning so close to the earnings, should we expect to see any surprises? Visa has been making strong moves with Visa Europe acquisition, partnership with PayPal and a 15% increase if quarterly dividends.

User Vishnu Beri {{ '2016-10-24T17:05:39+0000' | timeago}}

Kimberly Clark Corp ($KMB) has been in decline for most of the year, the stock has also not been getting any analyst love. Will today’s earnings break the trend? Revenue has been up and down in the last four quarters, let us see what this quarter brings.

User Floyd Jenks {{ '2016-10-24T15:53:54+0000' | timeago}}

$KMB down close to 4% after it misses on earnings and revenue. Forecasts are lower for the year.

$CAT {{ '2016-10-25T12:21:34+0000' | timeago}} • Announcement

$CAT expects 2016 sales and revenues of about $39Bil, and profit of $2.35 per share, or $3.25 per share excluding restructuring costs. This is down from the previously expected sales and revenues range of $40.0-40.5Bil. Restructuring costs in 2016 are now forecast to be about $800MM, mainly due to asset write downs recognized in 3Q16.

$CAT {{ '2016-10-25T12:18:08+0000' | timeago}} • Announcement

$CAT reported lower earnings in 3Q16, hurt by a decrease in sales and revenues compared to 3Q15. Profit was $283MM or $0.48 per diluted share compared to $559MM or $0.94 per diluted share last year. Total sales and revenues declined $1.802Bil or 16% from last year to $9.16Bil. Excluding restructuring costs, profit per share was $0.85 in 3Q16.

$UTX {{ '2016-10-25T12:17:33+0000' | timeago}} • Announcement

Diversified industrial major $UTX reported a higher quarterly profit as its Pratt & Whitney and aerospace systems divisions drove revenue. Earnings from continuing operations attributable to common shareholders rose to $1.74 per share from $1.61 in 3Q16. Revenue rose 4% to $14.35Bil.

$MRK {{ '2016-10-25T12:17:28+0000' | timeago}} • Webcast

$MRK said on October 24, 2016, the US Food and Drug Administration (FDA) approved KEYTRUDA as the only PD-L1 therapy for the first-line treatment of metastatic lung cancer. In 3Q16, the company reported a strong performance, reflecting growth across several priority programs, including the vaccines portfolio and also KEYTRUDA and ZEPATIER.

$PG {{ '2016-10-25T12:10:37+0000' | timeago}} • Infographic

$PG Procter & Gamble Earnings AlphaGraph: Q1 2017 Highlights